Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Helm, Ole ^a   Mennrich, Ruben ^a   Petrick, Domantas ^a   Goebel, Lisa ^a   Freitag Wolf, Sandra ^a   Röder, Christian ^a   Kalthoff, Holger ^a   Röcken, Christoph ^a   Sipos, Bence ^b   Kabelitz, Dieter ^a   Schäfer, Heiner ^c   Oberg, Hans Heinrich ^a   Wesch, Daniela ^a   Sebens, Susanne ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c Laboratory of Molecular Gastroenterology and Hepatology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; VIMENTIN; DIFFERENTIATION ANTIGEN; TUMOR PROTEIN;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CARCINOMA CELL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CHRONIC PANCREATITIS; CONTROLLED STUDY; FEMALE; FIBROBLAST; FOXP3+ CD4+ T LYMPHOCYTE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SPACE; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; STROMA CELL; TUMOR DIFFERENTIATION; BIOSYNTHESIS; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; EPITHELIUM; GENE EXPRESSION REGULATION; MACROPHAGE; METABOLISM; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PANCREATITIS; PATHOLOGY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIGENS, DIFFERENTIATION; CARCINOMA, PANCREATIC DUCTAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; EPITHELIUM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; PANCREATITIS; STROMAL CELLS; SURVIVAL RATE;

EID: 84900424891     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094357     Document Type: Article

References (37)

1. Siegel R, Naishadham D, Jemal A. (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29.
2. Schneider G, Siveke JT, Eckel F, Schmid RM. (2005) Pancreatic cancer: basic and clinical aspects. Gastroenterology 128:1606-25. (Pubitemid 40692555)
3. Esposito I, Konukiewitz B, Schlitter AM, Klöppel G. (2012) Neue Einblicke in die Entstehung des Pankreaskarzinoms. Pathologe [Suppl 2] 33: 189-193.
4. Farrow B, Evers BM. (2002) Inflammation and the development of pancreatic cancer. Surg Oncol 10:153-69. (Pubitemid 34520439)
5. Kleeff J, Beckhove P, Esposito I, Herzig S, Huber PE, et al. (2007) Pancreatic cancer microenvironment. Int J Cancer 121:699-705. (Pubitemid 47106197)
6. Fujita H, Ohuchida K, Mizumoto K, Nakata K, Yu J, et al. (2010) alpha-Smooth Muscle Actin Expressing Stroma Promotes an Aggressive Tumor Biology in Pancreatic Ductal Adenocarcinoma. Pancreas. [Epub ahead of print]
7. Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, et al. (2009) Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 167:e211-219.
8. Kurahara H, Takao S, Maemura K, Mataki Y, Kuwahata T, et al. (2013) M2-Polarized Tumor-Associated Macrophage Infiltration of Regional Lymph Nodes Is Associated With Nodal Lymphangiogenesis and Occult Nodal Involvement in pN0 Pancreatic Cancer. Pancreas 42:155-159.
9. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, et al. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756-2761. (Pubitemid 34921025)
10. Hiraoka N, Onozato K, Kosuge T, Hirohashi S. (2006) Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12:5423-5434. (Pubitemid 44497257)
11. De Monte L, Reni M, Tassi E, Clavenna D, Papa I, et al. (2011) Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208:469-478.
12. Protti MP, De Monte L. (2013) Immune infiltrates as predictive markers of survival in pancreatic cancer patients. Front Physiol 4:210.
13. Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, et al. (2013) Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 108:914-923.
14. Shojaei H, Oberg HH, Juricke M, Marischen L, Kunz M, et al. (2009) Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human γδ-T cells. Cancer Res 69:8710-9716.
15. Kabelitz D, Kalyan S, Oberg HH, Wesch D. (2013) Human Vδ2 versus non-Vδ2 γδ-T cells in antitumor immunity. OncoImmunology 2:e23304.
16. Geismann C, Morscheck M, Koch D, Ungefroren H, Arlt A, et al. (2009) Upregulation of L1CAM in pancreatic duct cells is transforming Growth Factor β1- and Slug-dependent: Role in malignant transformation of pancreatic cancer. Cancer Res 69:4517-4526.
17. Kiefel H, Bondong S, Hazin J, Ridinger J, Schirmer U, et al. (2012) L1CAM: a major driver for tumor cell invasion and motility. Cell Adh Migr 6:374-384.
18. Kiefel H, Bondong S, Pfeifer M, Schirmer U, Erbe-Hoffmann N, et al. (2012) EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-κB activation. Carcinogenesis 33:1919-1929.
19. Sebens Müerköster S, Werbing V, Sipos B, Debus MA, Witt M, et al. (2007) Drug-induced expression of the cellular adhesion molecule L1CAM confers antiapoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 26:2759-2768.
20. Bergmann F, Wandschneider F, Sipos B, Moldenhauer G, Schniewind B, et al. (2010) Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarinoma. Oncology Rep 24:909-915.
21. Ben Q-W, Wang J-C, Liu J, Zhu Y, Yuan F, et al. (2010) Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann Surg Oncol 17:2213-2221.
22. Schäfer H, Geismann C, Heneweer C, Egberts J-H, Korniienko O, et al. (2012) Myofibroblast-induced tumorigenicity of pancreatic ductal epithelial cells is L1CAM-dependent. Carcinogenesis 33:84-93.
23. Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grüssel S, et al. (2007) Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 67:8344-8350. (Pubitemid 47395173)
24. Kim M, Grimmig T, Grimm M, Lazariotou M,Meier E, et al. (2013) Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer. PLoS One 8:e53630.
25. Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, et al. (2008) Foxp3 expression in human cancer cells. J Transl Med 6:19.
26. Emmrich J, Weber I, Nausch M, Sparmann G, Koch K, et al. (1998) Immunohistochemical characterization of the pancreatic cellular infiltrate in normal pancreas, chronic pancreatitis and pancreatic carcinoma. Digestion 59:192-198. (Pubitemid 28246387)
27. Oberg H-H, Peipp M, Kellner C, Sebens S, Krause S, et al. (2014) Novel bispecific antibodies increase the γδ-T cell cytotoxicity against pancreatic cancer cells. Cancer Res. 2014 Jan 21. [Epub ahead of print]
28. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, et al. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:1457-1461.
29. Hartel M, Di Mola FF, Gardini A, Zimmermann A, Di Sebastiano P, et al. (2004) Desmoplastic reaction influences pancreatic cancer growth behavior. World J Surg 28:818-825. (Pubitemid 39315401)
30. Müerköster S, Wegehenkel K, Arlt A, Witt M, Sipos B, et al. (2004) Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 64:1331-1337.
31. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, et al. (2012) EMT and dissemination precede pancreatic tumor formation. Cell 148:349-361.
32. Liu CY, Xu JY, Shi XY, Huang W, Ruan TY, et al. (2013) M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Invest 93:844-854.
33. Helm O, Held-Feindt J, Grage-Griebenow E, Reiling N, Ungefroren U, et al. (2014) Tumor associated macrophages exhibit pro- and anti-inflammatory properties by which they impact on pancreatic tumorigenesis. Int J Cancer. 2014 Jan 23. [Epub ahead of print].
34. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, et al. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1:54-67.
35. Pilarsky C, Ammerpohl O, Sipos B, Dahl E, Hartmann A, et al. (2008) Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J Cell Mol Med (6B):2823-2835.
36. Meraviglia S, Caccamo N, Guggino G, Tolomeo M, Siragusa S, et al. 2010. Optimizing tumor-reactive γδ-T cells for antibody-based cancer immunotherapy. Curr Mol Med 10:719-726.
37. Gardian K, Janczewska S, Olszewski WL, Durlik M. (2012) Analysis of pancreatic cancer microenvironment: role of macrophage infiltrates and growth factors expression. J Cancer 3:285-291.